

# Joyce C Mhlanga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5332492/publications.pdf>

Version: 2024-02-01

9  
papers

64  
citations

1937685  
4  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

58  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2235-2245.	1.6	21
2	A Bayesian approach to tissue-fraction estimation for oncological PET segmentation. <i>Physics in Medicine and Biology</i> , 2021, 66, 124002.	3.0	14
3	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. <i>British Journal of Radiology</i> , 2019, 92, 20180930.	2.2	10
4	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2932.	3.7	5
5	Comparison of radiation dose and image quality between contrast-enhanced single- and dual-energy abdominopelvic computed tomography in children as a function of patient size. <i>Pediatric Radiology</i> , 2021, 51, 2000-2008.	2.0	4
6	Myocardial uptake of <sup>68</sup> Ga-DOTATATE: correlation with cardiac disease and risk factors. <i>Acta Radiologica</i> , 2022, 63, 1166-1172.	1.1	4
7	MR-assisted PET respiratory motion correction using deep learning based short-scan motion fields. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 676-690.	3.0	4
8	<sup>18</sup> F-FDG PET in Myocardial Viability Assessment: A Practical and Time-Efficient Protocol. <i>Journal of Nuclear Medicine</i> , 2022, 63, 602-608.	5.0	2
9	<sup>18</sup> F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 525-534.	1.7	0